Throughout Melanoma Awareness Month, all new gifts to MRA will be doubled. Join us in saving, protecting, and funding melanoma research.
Donate Today
MRA is the world’s largest private nonprofit funder of melanoma research, and 100% of every donation goes to our research portfolio. We’ve directly invested over $200 million toward scientific discoveries and research grants. We won’t stop until we achieve our mission of curing melanoma.
We’re scientists, clinicians, patients, caregivers, and advocates who are committed to curing melanoma by advancing research.
We fund the boldest, and most promising melanoma skin cancer research worldwide while supporting patients and families every step of the way.
We’re the largest nonprofit funder across the entire spectrum of melanoma research. Thanks to the ongoing generosity of our founders, 100% of all donations are invested directly in research.
It’s easy to feel overwhelmed when facing melanoma. If you or someone you love has melanoma, we have the resources you need.
Do you have questions? Looking for support? Join other patients, caregivers, friends, and family who know first hand what it’s like to face melanoma.
9 out of 10 skin cancers, including melanoma, are preventable. Get the tips you need to keep yourself and those you love sun safe.
When it comes to melanoma, a screening could save your life. Learn what to look for, how to perform a self check, & more!
Since MRA’s founding, an unprecedented 20 new therapies have been approved by the FDA to treat melanoma.
Every patient deserves a path forward, including those facing melanoma’s hardest-to-treat types. From improving early diagnosis to confronting rare melanomas and disease that spreads to the brain, explore the research priorities driving MRA’s next chapter.
Acral, mucosal, pediatric, and uveal melanomas – what we collectively call rare melanomas – represent an area of profound unmet medical need. MRA is investing heavily to ensure patients facing these rare subtypes aren’t left behind, including the launch of our RARE Registry.
Although treatment options for advanced melanoma have improved, many patients either do not respond to treatment at all, or initially respond but then at a later point progress despite treatment. In either case, it is critical to identify new treatment options for this patient population.
Melanoma is the third most common source of brain metastases and has one of the highest rates of leptomeningeal disease. Considerable work is still needed to fully understand where central nervous system metastases originate and how they progress, in order to identify better treatment strategies.
Preventing melanoma, finding it as early as possible, and getting the right diagnosis from the start are critical to curbing rates of melanoma and ensuring optimal patient survival.
Learn more:
Advancing our understanding of rare subtypes of melanoma, such as acral and mucosal melanoma.
Read the Report
We’ve made it easier than ever to raise funds to advance melanoma research! Run a marathon, dedicate your birthday or wedding, or share your own story about melanoma with friends to make the pitch.
MRA hosts several major events throughout the year that bring together world renowned researchers, physicians, patient advocates, donors, and partners, all working to advance melanoma research.
Learn More
